You just clicked a link to go to another website. If you continue, you will leave this site and go to a site run by someone else.
It is possible that some of the products on the other site not be licensed for sale in Canada.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
By choosing to accept, you acknowledge that you are a Certified Healthcare Professional.
TAVI is a minimally invasive, catheter-based procedure to replace the function of the aortic valve. Indicated for patients at intermediate or greater risk for open heart surgery, TAVI may be an excellent option for certain patients because the prevalence of aortic stenosis and co-morbidities may increase the risks associated with surgical aortic valve replacement (SAVR).
The Evolut™ TAVI System is the only TAVI platform on the market that demonstrates significantly better outcomes in all-cause mortality or stroke over surgery in high-risk patients at 3 years.1
Designed for large EOAs, low gradients, and minimal patient prosthesis mismatch, the Evolut TAV allows your patient to return to activity faster.*SEE THE DATA
Five-year results demontstrated meaningful treatment for patients with sever symptomatic aortic stenosis.†SEE THE DATA
Popma JJ. SURTAVI: Two Year Complete Results from a Randomized Trial of a Self-expanding Transcatheter Heart Valve vs. Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis at Intermediate Surgical Risk. Presented at TCT 2018; San Diego, CA.
Deeb, et. al, J Am Coll Cardiol. 3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Implantation, 2016 Jun 7;67(22):2565-74.